Imagine the negative PR if AMRN withdrew from the US market for solely financial reasons ( we can make more $ in the EU ) …and the generics with limited supply … could not fill that void .
It’s like Martin Shrelli (?) who jacked up the price of the drug his company controlled this denying patient access .
If Amarins actions end up limiting Vascepa supply to US CAD patients already on Vascepa …. They will be sued ….if the reason they limited supply was purely for their financial benefit ( ie they can make more in the EU )
Market Data 
Markets 
AI
